Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01790152 · ClinicalTrials.gov registry record
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
A clinical trial of Osteosarcoma and Lymphoblastic Lymphoma, sponsored by Children's Oncology Group.
- Recruiting
- Registry status
- 420
- Enrollment target
- 20
- Study locations
NCT01790152: Recruiting study of Osteosarcoma and Lymphoblastic Lymphoma, sponsored by Children's Oncology Group.
NCT01790152 is a study of Osteosarcoma and Lymphoblastic Lymphoma that is actively recruiting participants, run by Children's Oncology Group. The registered enrollment target is 420 participants, above the 293-participant average among 46 other Osteosarcoma trials with a reported enrollment target (43% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01790152, a study of Osteosarcoma and Lymphoblastic Lymphoma, is actively recruiting participants, sponsored by Children's Oncology Group.
- RECRUITING
- Registry status
- 420 participants
- Enrollment target
- 20
- Study locations
Study Summary
This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory from patients receiving dexrazoxane hydrochloride may help doctors learn more about the effects of dexrazoxane hydrochloride on cells. It may also help doctors understand how well patients respond to treatment.
Primary Outcome
Univariate tests will be used as well as examination of the entire cohort via multivariable regression adjusting for all a priori covariates of interest.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Laboratory Biomarker Analysis
- OTHER Questionnaire Administration
- OTHER Assessment of Therapy Complications
Study Locations (20)
Florida
- Golisano Children's Hospital of Southwest Florida - Fort Myers
- University of Florida Health Science Center - Gainesville - Gainesville
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital - Hollywood
- Nemours Children's Clinic-Jacksonville - Jacksonville
- Nemours Children's Hospital - Orlando
- Johns Hopkins All Children's Hospital - St. Petersburg
- Saint Joseph's Hospital/Children's Hospital-Tampa - Tampa
- Saint Mary's Hospital - West Palm Beach
California
- City of Hope Comprehensive Cancer Center - Duarte
- Valley Children's Hospital - Madera
- Kaiser Permanente-Oakland - Oakland
- Lucile Packard Children's Hospital Stanford University - Palo Alto
- Rady Children's Hospital - San Diego - San Diego
Arizona
- Phoenix Childrens Hospital - Phoenix
- Banner University Medical Center - Tucson - Tucson
Alabama
- Children's Hospital of Alabama - Birmingham
Arkansas
- Arkansas Children's Hospital - Little Rock
Connecticut
- Yale University - New Haven
Georgia
- Children's Healthcare of Atlanta - Egleston - Atlanta
Hawaii
- University of Hawaii Cancer Center - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2014-03-05 |
| Est. Completion | 2025-12-31 |
What NCT01790152 shows while recruiting
NCT01790152 is an observational study that tracks outcomes without assigning an intervention. The registered 420 participants enrollment target is mid-sized for trials with a published cap, above the 293-participant average among 46 other Osteosarcoma trials with a reported enrollment target (43% higher).
The record links to 7 conditions, with Osteosarcoma appearing as the primary indexed condition, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.
NCT01790152 names 20 study sites across 8 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT01790152 about?
NCT01790152 is a clinical study titled "Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment". This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory from patients receiving dexrazoxane hydrochloride may help doctors learn more about the effects of d...
What is the current status of trial NCT01790152?
This trial is currently recruiting. The enrollment target is 420 participants. The study started on 2014-03-05. Estimated completion is 2025-12-31.
What conditions does trial NCT01790152 study?
This clinical trial studies the following conditions: Osteosarcoma, Lymphoblastic Lymphoma, Recurrent Malignant Neoplasm, Recurrent Lymphoma, Recurrent Leukemia.
What interventions are being tested in trial NCT01790152?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Laboratory Biomarker Analysis (OTHER), Questionnaire Administration (OTHER), Assessment of Therapy Complications (OTHER).
Who is sponsoring clinical trial NCT01790152?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01790152 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01790152's enrollment target sits among peer trials
420 3rd of 46 higher than 44 of 46 other Osteosarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteosarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Losartan + Sunitinib in Treatment of Osteosarcoma
RECRUITING · Phase 1
-
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
RECRUITING · Phase 3
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701244 · 420 participants
A Registry Study of Breast Microseed Treatment
- NCT02966665 · 420 participants · Phase 1
: Vascular Function in Health and Disease
- NCT04149743 · 420 participants · NA
HEMOTAG® Assessment for Short-term Outcomes of Heart Failure
- NCT05097976 · 420 participants · Phase 4
Medrol Dosepak for Outpatient Total Knee Arthroplasty
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI